What is Korsana Biosciences, Inc.'s earnings per share (EPS)?

Korsana Biosciences, Inc. (KRSA) reported diluted earnings per share of -$1.11 for fiscal year 2025. This represents a 8.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Korsana Biosciences, Inc. (KRSA) Financials

KRSA

FY2025 annual

Revenue $2.1M +3.7% YoY

Net Income -$3.5M -15.4% YoY

EPS (Diluted) -$1.11 +8.3% YoY

Operating Cash Flow -$3.3M +23.5% YoY

Market Cap $1.6B as of Sep 22, 2026

Price / Sales 768x on $2.1M revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 313x on $5.1M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KRSA SEC filings page.

Korsana Biosciences, Inc. (KRSA) reported $2.1M in revenue for fiscal year 2025, up 3.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Health Score 59/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Korsana Biosciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Korsana Biosciences, Inc. held $8.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $3.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Korsana Biosciences, Inc. scores 57/100 among other emerging companies.

Dilution

Korsana Biosciences, Inc. had 4M shares outstanding at the end of fiscal year 2025, against 3M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Korsana Biosciences, Inc. scores 28/100 among other emerging companies.

R&D Intensity

Korsana Biosciences, Inc. spent $959K on research and development in fiscal year 2025, which was 13.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Korsana Biosciences, Inc. scores 42/100 among other emerging companies.

Revenue Progress

Korsana Biosciences, Inc. reported revenue of $2.1M in fiscal year 2025, against $2.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Korsana Biosciences, Inc. scores 48/100 among other emerging companies.

Burn Trend

Korsana Biosciences, Inc.'s operations used $3.3M of cash in fiscal year 2025, against $4.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Korsana Biosciences, Inc. scores 83/100 among other emerging companies.

Balance Sheet

Korsana Biosciences, Inc.'s cash, cash equivalents and investments came to $8.6M at the end of fiscal year 2025, against $900K of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Korsana Biosciences, Inc. scores 96/100 among other emerging companies.

Altman Z-Score Safe

1023.04

Korsana Biosciences, Inc. scores 1023.04, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.6B) relative to total liabilities ($900K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Korsana Biosciences, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Korsana Biosciences, Inc. reported a net loss of $3.5M while operations used $3.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$1.8M

YoY-441.7%

QoQ+44.8%

Korsana Biosciences, Inc. reported -$1.8M in net income in Q2 2026. This represents a decrease of 441.7% from the same quarter a year earlier. Against the prior quarter it is up 44.8%.

EPS (Diluted)

-$0.41

YoY-272.7%

QoQ+46.1%

Korsana Biosciences, Inc. earned -$0.41 per diluted share (EPS) in Q2 2026. This represents a decrease of 272.7% from the same quarter a year earlier. Against the prior quarter it is up 46.1%.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$1.4M

YoY-184.7%

QoQ-15.3%

Korsana Biosciences, Inc. recorded an outflow of $1.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 184.7% from the same quarter a year earlier. Against the prior quarter it is down 15.3%.

Cash & Debt

$1.4M

YoY-53.7%

QoQ-50.7%

5Y CAGR-54.4%

Korsana Biosciences, Inc. held $1.4M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY+40.3%

QoQ+8.1%

5Y CAGR-35.9%

Korsana Biosciences, Inc. had 5M shares outstanding in Q2 2026. This represents an increase of 40.3% from the same quarter a year earlier. Against the prior quarter it is up 8.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-34.5%

YoY-30.7pp

QoQ+12.3pp

Korsana Biosciences, Inc.'s ROE was -34.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 30.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

Capital Expenditures

QoQ-100.0%

Korsana Biosciences, Inc. reported no capital expenditure in Q2 2026. Against the prior quarter it is down 100.0%.

R&D Spending

Not reported for Q2 2026.

Share Buybacks

Not reported for Q2 2026.

KRSA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KRSA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Revenue	N/A	$2.1M+3.7%	$2.0M	$0-100.0%	$297K-92.5%	$3.9M+71.7%	$2.3M-49.1%	$4.5M	N/A
R&D Expenses	N/A	$959K+235.3%	$286K-81.1%	$1.5M-74.7%	$6.0M-84.1%	$37.6M-33.3%	$56.4M-40.7%	$95.1M	N/A
SG&A Expenses	$7.1M	$6.1M+14.0%	$5.3M-34.3%	$8.1M-36.8%	$12.9M-37.6%	$20.6M-28.4%	$28.8M-16.2%	$34.4M+24.9%	$27.5M
Operating Income	-$6.8M	-$5.0M-37.1%	-$3.6M+72.0%	-$13.0M+30.1%	-$18.5M+66.4%	-$55.2M+32.1%	-$81.3M+35.0%	-$125.0M	N/A
EBITDA	N/A	N/A	N/A	-$13.0M+29.9%	-$18.5M+66.2%	-$54.7M+30.7%	-$79.0M+35.5%	-$122.3M	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	-$6.7M	-$3.5M-15.4%	-$3.1M+41.9%	-$5.3M+88.1%	-$44.1M+14.7%	-$51.6M+33.6%	-$77.8M+36.8%	-$123.0M	N/A
EPS (Basic)	N/A	-$1.11+8.3%	-$1.21+46.2%	-$2.25+88.9%	-$20.28-1436.4%	-$1.32	N/A	N/A	N/A
EPS (Diluted)	-$1.66	-$1.11+8.3%	-$1.21+46.2%	-$2.25	-$20.28	-$1.32	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	3M+26.3%	3M+7.7%	2M	2M	39M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-K	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-K	Q4'2410-K	Q3'2410-Q
Revenue	N/A	$0-100.0%	$1.0M	$875K+351.0%	$93K	$81K	N/A	$194K
R&D Expenses	N/A	$730K+1927.8%	$519K	$348K+329.6%	$56K-46.7%	$36K-18.2%	N/A	$81K-86.0%
SG&A Expenses	$1.8M+3.6%	$2.5M+65.0%	$1.3M	$1.5M+23.5%	$1.7M+33.6%	$1.5M-4.6%	N/A	$1.2M-41.8%
Operating Income	-$1.8M-5.9%	-$3.2M-120.2%	-$838K	-$1.0M+10.8%	-$1.7M-20.8%	-$1.5M+10.0%	N/A	-$1.1M+81.2%
Net Income	-$1.8M-441.7%	-$3.2M-122.3%	-$799K	-$976K-35.0%	-$324K+75.5%	-$1.4M+7.3%	N/A	-$723K-109.6%
EPS (Basic)	-$0.41-272.7%	-$0.76-35.7%	-$0.19-186.4%	-$0.30-3.4%	-$0.11+79.2%	-$0.56+9.7%	$0.22+131.4%	-$0.29-109.4%
EPS (Diluted)	-$0.41-272.7%	-$0.76	-$0.19-186.4%	-$0.30-3.4%	-$0.11+79.2%	-$0.56+9.7%	$0.22+131.4%	-$0.29-110.7%
Diluted Shares (Avg)	4M+38.4%	4M	N/A	3M+27.7%	3M+22.4%	3M+2.5%	N/A	3M-9.3%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.

KRSA Balance Sheet

KRSA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Total Assets	$10.0M+4.3%	$9.6M-28.4%	$13.4M-26.0%	$18.1M-69.5%	$59.3M-48.6%	$115.4M-38.1%	$186.5M+2419.6%	$7.4M
Current Assets	$4.6M+9.7%	$4.2M-47.3%	$8.0M-45.9%	$14.8M-73.3%	$55.5M-5.2%	$58.5M-42.2%	$101.2M+11412.7%	$879K
Cash & Equivalents	$3.2M+0.2%	$3.2M-57.3%	$7.6M-43.4%	$13.4M-75.2%	$54.0M-0.8%	$54.4M-42.7%	$94.9M	$0
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$1.0M+79.9%	$556K	$0-100.0%	$96K-4.0%	$100K	$0	N/A	N/A
Long-Term Investments	$5.3M0.0%	$5.3M0.0%	$5.3M	$0	$0	$0	$0	$0
Total Liabilities	$900K+24.1%	$725K-65.2%	$2.1M-72.6%	$7.6M-31.2%	$11.1M-80.2%	$55.9M-37.0%	$88.7M+397.3%	$17.8M
Current Liabilities	$900K+24.1%	$725K-65.2%	$2.1M-72.6%	$7.6M-31.2%	$11.1M-34.6%	$17.0M-7.1%	$18.2M+2.3%	$17.8M
Non-Current Liabilities	$0	$0	$0	$0	$0-100.0%	$38.9M-44.8%	$70.5M	$0
Total Equity	$9.1M+2.7%	$8.8M-21.6%	$11.3M+8.0%	$10.5M-78.3%	$48.2M-18.9%	$59.5M-39.1%	$97.7M+1035.7%	-$10.4M
Retained Earnings	-$271.0M-1.3%	-$267.5M-1.2%	-$264.4M-2.0%	-$259.2M-20.5%	-$215.1M-31.6%	-$163.4M-90.9%	-$85.6M	N/A

Metric	Q2'2610-Q	Q1'2610-K	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-K	Q4'2410-K	Q3'2410-Q
Total Assets	$6.9M-26.0%	$8.5M-13.6%	$10.0M+4.3%	$10.4M+17.0%	$9.4M-6.9%	$9.8M-13.3%	$9.6M-28.4%	$8.9M-41.5%
Current Assets	$1.5M-62.3%	$3.1M-31.3%	$4.6M+9.7%	$5.1M+42.8%	$4.0M-14.7%	$4.5M-25.2%	$4.2M-47.3%	$3.5M-64.0%
Cash & Equivalents	$1.4M-53.7%	$2.8M-22.4%	$3.2M+0.2%	$4.6M+59.1%	$3.0M-34.5%	$3.6M-36.1%	$3.2M-57.3%	$2.9M-68.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$0-100.0%	$0-100.0%	$1.0M+79.9%	$100K+127.3%	$525K	$581K	$556K	$44K
Long-Term Investments	$5.3M0.0%	$5.3M0.0%	$5.3M0.0%	$5.3M0.0%	$5.3M0.0%	$5.3M0.0%	$5.3M0.0%	$5.3M0.0%
Total Liabilities	$1.8M+130.4%	$1.7M+60.6%	$900K+24.1%	$877K+25.3%	$800K-37.6%	$1.1M-26.0%	$725K-65.2%	$700K-70.1%
Current Liabilities	$1.8M+130.4%	$1.7M+60.6%	$900K+24.1%	$877K+25.3%	$800K-37.6%	$1.1M-26.0%	$725K-65.2%	$700K-70.1%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$5.1M-40.6%	$6.8M-22.7%	$9.1M+2.7%	$9.5M+16.3%	$8.6M-2.4%	$8.8M-11.5%	$8.8M-21.6%	$8.2M-36.3%
Retained Earnings	-$276.0M-2.5%	-$274.2M-2.0%	-$271.0M-1.3%	-$270.2M-0.8%	-$269.2M-0.7%	-$268.9M-1.1%	-$267.5M-1.2%	-$268.0M-2.0%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

KRSA Cash Flow Statement

KRSA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Cash Flow	-$4.5M	-$3.3M+23.5%	-$4.3M+79.6%	-$21.2M+47.7%	-$40.6M-11.2%	-$36.5M+49.6%	-$72.5M+29.1%	-$102.2M	N/A
Depreciation & Amortization	N/A	N/A	N/A	$0-100.0%	$65K-86.2%	$472K-79.5%	$2.3M-14.9%	$2.7M+76.7%	$1.5M
Stock-Based Compensation	N/A	$441K-29.4%	$625K-41.4%	$1.1M-82.9%	$6.3M-34.9%	$9.6M-35.9%	$15.0M-23.6%	$19.6M+57.9%	$12.4M
Capital Expenditures	N/A	N/A	N/A	N/A	$0-100.0%	$7K-99.5%	$1.5M-77.9%	$6.9M+100.3%	$3.4M
Free Cash Flow	N/A	N/A	N/A	N/A	-$40.6M-11.2%	-$36.5M+50.7%	-$74.0M+32.2%	-$109.1M	N/A
Investing Cash Flow	N/A	N/A	$0-100.0%	$10.4M	$0-100.0%	$1.5M+7994.4%	$18K+100.3%	-$6.7M-95.3%	-$3.4M
Financing Cash Flow	$2.9M	$3.3M	$0-100.0%	$5.0M+17224.1%	$29K-99.9%	$30.8M+9.6%	$28.1M-86.7%	$211.6M	N/A

Metric	Q2'2610-Q	Q1'2610-K	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-K	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.4M-184.7%	-$1.2M-21.5%	-$1.6M-538.6%	-$264K+84.6%	-$503K+54.5%	-$968K+48.3%	$360K+123.4%	-$1.7M+75.3%
Stock-Based Compensation	$51K-55.3%	$58K-49.1%	N/A	$118K-14.5%	$114K-38.0%	$114K-37.0%	N/A	$138K-13.2%
Capital Expenditures	$0	$66K	N/A	N/A	$0	$0	N/A	N/A
Free Cash Flow	-$1.4M-184.7%	-$1.2M-28.3%	N/A	N/A	-$503K	-$968K	N/A	N/A
Investing Cash Flow	$0	-$66K	N/A	N/A	$0	$0	$0	$0-100.0%
Financing Cash Flow	$0+100.0%	$825K-40.0%	$251K	$1.8M	-$130K	$1.4M	$0	$0

Not reported in any period shown, so not listed: Depreciation & Amortization, Dividends Paid, Share Buybacks.

KRSA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KRSA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Margin	-239.8%	-181.4%	N/A	-6242.4%	-1400.2%	-3539.4%	-2774.3%	N/A
Net Margin	-170.1%	-152.8%	N/A	-14841.1%	-1310.2%	-3388.6%	-2729.3%	N/A
Return on Equity	-38.8%-4.3pp	-34.5%+12.1pp	-46.6%+375.1pp	-421.7%-314.7pp	-107.0%+23.7pp	-130.8%-4.9pp	-125.9%	N/A
Return on Assets	-35.3%-3.4pp	-31.9%+7.4pp	-39.4%+204.5pp	-243.8%-156.8pp	-87.1%-19.6pp	-67.4%-1.5pp	-66.0%	N/A
Current Ratio	5.15-0.7x	5.83+2.0x	3.85+1.9x	1.94-3.1x	5.00+1.6x	3.45-2.1x	5.55+5.5x	0.05
Debt-to-Equity	0.100.0x	0.08-0.1x	0.18-0.5x	0.73+0.5x	0.23-0.7x	0.940.0x	0.91	N/A
Asset Turnover	0.210.0x	0.21+0.2x	0.000.0x	0.02-0.1x	0.070.0x	0.020.0x	0.02	N/A
FCF Margin	N/A	N/A	N/A	-13673.7%	-926.5%	-3223.6%	-2420.7%	N/A

Metric	Q2'2610-Q	Q1'2610-K	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-K	Q4'2410-K	Q3'2410-Q
Operating Margin	N/A	N/A	-81.8%	-115.0%	-1797.8%	-1798.8%	N/A	-581.4%
Net Margin	N/A	N/A	-78.0%	-111.5%	-348.4%	-1764.2%	N/A	-372.7%
Return on Equity	-34.5%-30.7pp	-46.8%-30.5pp	-8.8%	-10.2%-1.4pp	-3.8%+11.3pp	-16.3%-0.7pp	N/A	-8.8%-67.6pp
Return on Assets	-25.3%-21.9pp	-37.4%-22.8pp	-8.0%	-9.4%-1.2pp	-3.5%+9.7pp	-14.5%-0.9pp	N/A	-8.1%-57.9pp
Current Ratio	0.82-4.2x	1.80-2.4x	5.15-0.7x	5.78+0.7x	5.03+1.3x	4.210.0x	5.83+2.0x	5.07+0.9x
Debt-to-Equity	0.36+0.3x	0.25+0.1x	0.100.0x	0.090.0x	0.09-0.1x	0.120.0x	0.08-0.1x	0.09-0.1x
Asset Turnover	N/A	0.000.0x	0.10	0.08+0.1x	0.010.0x	0.010.0x	N/A	0.020.0x
FCF Margin	N/A	N/A	N/A	N/A	-540.9%	-1195.1%	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Where Korsana Biosciences, Inc. Ranks

Frequently Asked Questions

What is Korsana Biosciences, Inc.'s annual revenue?

Korsana Biosciences, Inc. (KRSA) reported $2.1M in total revenue for fiscal year 2025. This represents a 3.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Korsana Biosciences, Inc.'s revenue growing?

Korsana Biosciences, Inc. (KRSA) revenue grew by 3.7% year-over-year, from $2.0M to $2.1M in fiscal year 2025.

Is Korsana Biosciences, Inc. profitable?

No, Korsana Biosciences, Inc. (KRSA) reported a net income of -$3.5M in fiscal year 2025.

What is Korsana Biosciences, Inc.'s return on equity (ROE)?

Korsana Biosciences, Inc. (KRSA) has a return on equity of -38.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Korsana Biosciences, Inc.'s operating cash flow?

Korsana Biosciences, Inc. (KRSA) recorded an outflow of $3.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Korsana Biosciences, Inc.'s total assets?

Korsana Biosciences, Inc. (KRSA) had $10.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Korsana Biosciences, Inc. spend on research and development?

Korsana Biosciences, Inc. (KRSA) invested $959K in research and development during fiscal year 2025.

How many shares does Korsana Biosciences, Inc. have outstanding?

Korsana Biosciences, Inc. (KRSA) had 4M shares outstanding as of fiscal year 2025.

What is Korsana Biosciences, Inc.'s current ratio?

Korsana Biosciences, Inc. (KRSA) had a current ratio of 5.15 as of fiscal year 2025, which is generally considered healthy.

What is Korsana Biosciences, Inc.'s debt-to-equity ratio?

Korsana Biosciences, Inc. (KRSA) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Korsana Biosciences, Inc.'s return on assets (ROA)?

Korsana Biosciences, Inc. (KRSA) had a return on assets of -35.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Korsana Biosciences, Inc.'s P/E ratio?

Korsana Biosciences, Inc. (KRSA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.6B as of Sep 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Korsana Biosciences, Inc.'s price-to-sales ratio?

Korsana Biosciences, Inc. (KRSA) trades at 768x sales, its market capitalization divided by revenue of $2.1M revenue, FY2025. The market capitalization is $1.6B as of Sep 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Korsana Biosciences, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Korsana Biosciences, Inc. (KRSA) held $8.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.3M over that year. Dividing the one by the other, the reported balance equals about 31 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Korsana Biosciences, Inc.'s Altman Z-Score?

Korsana Biosciences, Inc. (KRSA) has an Altman Z-Score of 1023.04, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Korsana Biosciences, Inc.'s Piotroski F-Score?

Korsana Biosciences, Inc. (KRSA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Korsana Biosciences, Inc.'s earnings high quality?

Korsana Biosciences, Inc. (KRSA) reported a net loss of $3.5M while operations used $3.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Korsana Biosciences, Inc.?

Korsana Biosciences, Inc. (KRSA) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.